Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan

References

• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. doi:10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Mansour A, Jaddan D. Breast Cancer Care in Jordan. JCO Glob Oncol. 2020;6:260–268. doi:10.1200/JGO.19.00279
   PubMedGoogle Scholar
• Breast Cancer. American Cancer Society. Available from: https://www.cancer.org/cancer/breast-cancer.html. Accessed April 10, 2023.
   Google Scholar
• Ministry of Health: cancer incidence in Jordan; 2015. Available from https://www.moh.gov.jo/Pages/viewpage.aspx?pageID=240. Accessed September 18, 2023.
   Google Scholar
• Shamieh O, Hui D. A comprehensive palliative care program at a tertiary cancer center in Jordan. Am J Hosp Palliat Care. 2015;32(2):238–242. doi:10.1177/1049909113513316
   PubMed Web of Science ®Google Scholar
• Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end-of-life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24(21):3490–3496. doi:10.1200/JCO.2005.03.6236
   PubMed Web of Science ®Google Scholar
• Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–321. doi:10.1200/JCO.2004.08.136
   PubMed Web of Science ®Google Scholar
• Luta X, Maessen M, Egger M, Stuck AE, Goodman D, Clough-Gorr KM. Measuring intensity of end of life care: a systematic review. PLoS One. 2015;10(4):e0123764. doi:10.1371/journal.pone.0123764
   PubMed Web of Science ®Google Scholar
• Martins-Branco D, Lopes S, Canario R, et al. Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal. ESMO Open. 2020;5(6):e000953. doi:10.1136/esmoopen-2020-000953
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicenter, double-blind, Phase 3 randomized controlled trial. Lancet Oncol. 2016;17(4):425–439. doi:10.1016/S1470-2045(15)00613-0
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. Lancet Oncol. 2018;19(7):904–915. doi:10.1016/S1470-2045(18)30292-4
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a Phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. doi:10.1093/annonc/mdy155
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomized, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi:10.1093/annonc/mdz012
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Shamieh O, Alarjeh G, Li H, et al. Care Needs and Symptoms Burden of Breast Cancer Patients in Jordan: a Cross-Sectional Study. Int J Environ Res Public Health. 2022;19(17):10787. doi:10.3390/ijerph191710787
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742. doi:10.1056/NEJMoa1000678
   PubMed Web of Science ®Google Scholar
• Maltoni M, Scarpi E, Dall’Agata M, et al. Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016;69:110–118. doi:10.1016/j.ejca.2016.10.004
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, El-Jawahri A, et al. Effects of early integrated palliative care in patients with lung and GI cancer: a Randomized Clinical Trial. J Clin Oncol. 2017;35(8):834–841. doi:10.1200/JCO.2016.70.5046
   PubMed Web of Science ®Google Scholar
• Triplett DP, LeBrett WG, Bryant AK, et al. Effect of palliative care on aggressiveness of end-of-life care among patients with advanced cancer. J Oncol Pract. 2017;13(9):e760–e769. doi:10.1200/JOP.2017.020883
   PubMed Web of Science ®Google Scholar
• Scibetta C, Kerr K, Mcguire J, Rabow MW. The costs of waiting: implications of the timing of palliative care consultation among a cohort of decedents at a comprehensive cancer center. J Palliat Med. 2016;19(1):69–75. doi:10.1089/jpm.2015.0119
   PubMed Web of Science ®Google Scholar
• Wu CC, Hsu TW, Chang CM, Lee CH, Huang CY, Lee CC. Palliative chemotherapy affects aggressiveness of end-of-life care. Oncologist. 2016;21(6):771–777. doi:10.1634/theoncologist.2015-0445
   PubMed Web of Science ®Google Scholar
• Browner I, Carducci MA. Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol. 2005;32(2):145–155. doi:10.1053/j.seminoncol.2004.11.014
   PubMed Web of Science ®Google Scholar
• Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011;10:14. doi:10.1186/1472-684X-10-14
   PubMed Web of Science ®Google Scholar
• Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219. doi:10.1136/bmj.g1219
   PubMed Web of Science ®Google Scholar
• Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015;1(6):778–784. doi:10.1001/jamaoncol.2015.2378
   PubMed Web of Science ®Google Scholar
• Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(1):96–112. doi:10.1200/JCO.2016.70.1474
   PubMed Web of Science ®Google Scholar
• Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018;19(11):e588–e653. doi:10.1016/S1470-2045(18)30415-7
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S, Rodrigues LF, Shamieh O, et al. Perception of curability among advanced cancer patients: an international collaborative study. Oncologist. 2018;23(4):501–506. doi:10.1634/theoncologist.2017-0264
   PubMed Web of Science ®Google Scholar
• Amano K, Maeda I, Shimoyama S, et al. The accuracy of physicians’ clinical predictions of survival in patients with advanced cancer. J Pain Symptom Manage. 2015;50(2):139–46.e1. doi:10.1016/j.jpainsymman.2015.03.004
   PubMed Web of Science ®Google Scholar
• Hui D, Bansal S, Park M, et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015;26(7):1440–1446. doi:10.1093/annonc/mdv028
   PubMed Web of Science ®Google Scholar
• Guo P, Chukwusa E, Asad M, et al. Changing Mortality and Place of Death in Response to Refugee Influx: a Population-Based Cross-Sectional Study in Jordan, 2005-2016. J Palliat Med. 2021;24(11):1616–1625. doi:10.1089/jpm.2020.0476
   PubMed Web of Science ®Google Scholar
• Goodman DC, Morden NE, Chang CH, Fisher ES, Wennberg JE. Trends in Cancer Care Near the End of Life: A Dartmouth Atlas of Health Care Brief. Lebanon (NH): The Dartmouth Institute for Health Policy and Clinical Practice; 2013.
   Google Scholar
• Santini D, Zeppola T, Russano M, et al. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. J Transl Med. 2021;19(1):270. doi:10.1186/s12967-021-02937-9
   PubMed Web of Science ®Google Scholar
• Garrido MM, Prigerson HG. Chemotherapy use in the months before death and estimated costs of care in the last week of life. J Pain Symptom Manage. 2016;51(5):875–881.e2. doi:10.1016/j.jpainsymman.2015.12.323
   PubMed Web of Science ®Google Scholar
• Garrido MM, Balboni TA, Maciejewski PK, Bao Y, Prigerson HG. Quality of Life and Cost of Care at the End of Life: the Role of Advance Directives. J Pain Symptom Manage. 2015;49(5):828–835. doi:10.1016/j.jpainsymman.2014.09.015
   PubMed Web of Science ®Google Scholar
• Cheung MC, Earle CC, Rangrej J, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer N Cancer. 2015;121(18):3307–3315.
   PubMed Web of Science ®Google Scholar
• Karches KE, Chung GS, Arora V, Meltzer DO, Curlin FA. Religiosity, spirituality, and end- of- life planning: a single-site survey of medical inpatients. J Pain Symptom Manage. 2012;44(6):843–851. doi:10.1016/j.jpainsymman.2011.12.277
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Shamieh O, Abu-Nasser M, et al. Intensity of Cancer Care Near the End of Life at a Tertiary Care Cancer Center in Jordan. J Pain Symptom Manage. 2019;57(6):1106–1113. doi:10.1016/j.jpainsymman.2019.02.01
   PubMed Web of Science ®Google Scholar